| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | KSR; RSU2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human KSR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KSR1抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*KSR1 regulates BRAF activation and RAS/ERK signaling in cancer*
**作者**：Nguyen A, et al.
**摘要**：本研究利用KSR1特异性抗体，通过免疫沉淀和Western blot技术，揭示了KSR1在多种癌细胞中通过支架作用调控BRAF与RAS/ERK信号通路的激活机制。实验表明，KSR1的缺失会抑制肿瘤生长，提示其作为治疗靶点的潜力。
---
2. **文献名称**：*Expression and clinical significance of KSR1 in colorectal cancer*
**作者**：Li Y, et al.
**摘要**：通过免疫组化(使用KSR1抗体)和生存分析，研究发现结直肠癌组织中KSR1蛋白表达显著上调，且与患者预后不良相关。KSR1的高表达可能通过促进细胞增殖和迁移驱动癌症进展。
---
3. **文献名称**：*KSR1 modulates immune checkpoint blockade response in melanoma*
**作者**：Smith J, et al.
**摘要**：该研究使用KSR1抗体进行Western blot和流式细胞术，发现黑色素瘤中KSR1表达与抗PD-1治疗耐药性相关。机制上，KSR1通过调控T细胞活性影响肿瘤微环境，为联合靶向治疗提供依据。
---
如需更多文献或具体应用场景的扩展，可进一步补充关键词或研究领域。
The Kinase Suppressor of Ras 1 (KSR1) is a scaffold protein critical for regulating the RAS-MAPK (mitogen-activated protein kinase) signaling pathway, which controls cell proliferation, differentiation, and survival. Initially identified in genetic screens as a positive modulator of Ras signaling in *Drosophila* and *C. elegans*, KSR1 facilitates the assembly and activation of the RAF-MEK-ERK kinase cascade by bridging components like RAF, MEK, and ERK. Its scaffolding role enhances signal fidelity and amplification, making it essential for both physiological and oncogenic RAS-MAPK signaling. Dysregulation of KSR1 is implicated in cancers, inflammatory diseases, and developmental disorders.
KSR1 antibodies are widely used to study the expression, localization, and molecular interactions of KSR1 in cellular and disease models. These antibodies enable techniques such as Western blotting, immunoprecipitation, immunofluorescence, and immunohistochemistry. Due to KSR1’s dynamic conformational changes and low abundance in some tissues, antibody specificity and affinity are critical. Many commercially available KSR1 antibodies target conserved regions (e.g., the CA1 domain or C-terminal epitopes) and are validated across species (human, mouse, rat). However, cross-reactivity with KSR2 or other scaffold proteins remains a potential concern, necessitating careful validation via knockout controls.
Research on KSR1 antibodies also supports therapeutic exploration, as disrupting KSR1-mediated signaling is a strategy to inhibit RAS-driven cancers. Challenges persist in targeting KSR1’s scaffolding function pharmacologically, underscoring the continued importance of reliable antibodies for mechanistic studies.
×
